Art

J-GLOBAL ID：201702212969777085   Reference number：17A0981188

Sulfonylurea treatment in an infant with transient neonatal diabetes mellitus caused by an adenosine triphosphate binding cassette subfamily C member 8 gene mutation

アデノシン三リン酸結合カセットサブファミリーCメンバー8遺伝子変異により生じる一時的な新生児糖尿病の幼児のスルホニルウレア治療

Author (7)： Yamazaki Masayo (Department of Pediatrics, Jichi Medical University, Tochigi, Japan) ,  Sugie Hideo (Faculty of Health and Medical Sciences, Tokoha University, Shizuoka, Japan) ,  Oguma Makiko (Department of Pediatrics, Jichi Medical University, Tochigi, Japan) ,  Oguma Makiko (Department of Pediatrics, Japan Community Health care Organization Utsunomiya Hospital, Tochigi, Japan) ,  Yorifuji Tohru (Department of Pediatric Endocrinology and Metabolism, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan) ,  Tajima Toshihiro (Department of Pediatrics, Jichi Medical University, Tochigi, Japan) ,  Yamagata Takanori (Department of Pediatrics, Jichi Medical University, Tochigi, Japan)
Material： Clinical Pediatric Endocrinology  (Clin Pediatr Endocrinol)
Volume： 26  Issue： 3  Page： 165-169(J-STAGE)  Publication year： 2017 
JST Material Number： L4217A  ISSN： 0918-5739  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： Membrane Proteins ,...
Semi thesaurus term： *genetic variation ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0981188&from=J-GLOBAL&jstjournalNo=L4217A") }}

Author keywords (3)： transient neonatal diabetes mellitus (TNDM) ,  ABCC8 ,  sulfonylurea

JST classification (4)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F) ,  Clinical application of drugs acting on carbohydrate metabolism  (GW13030B) ,  Treatment for pediatric diseases.  (GC08040I) ,  Molecular genetics in general  (EC02010J)

Substance index (1)： Glibenclamide

Reference (8)：

• 1. Aguilar-Bryan, L, Bryan, J. Neonatal diabetes mellitus. Endocr Rev 2008;29: 265-91.
• 2. Greeley, SAW, Tucker, SE, Naylor, RN, Bell, GI, Philipson, LH. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab 2010;21: 464-72.
• 3. Suzuki, S, Koga, M, Amamiya, S, Nakao, A, Wada, K, Okuhara, K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011;54: 2247-53.
• 4. Hattersley, A. Transferring patients with diabetes due to a Kir6.2 mutation from insulin to sulphonylureas in patients who are aged under 1 year. http://www.diabetesgenes.org/content/transferring-patients-diabetes-due-kir62-mutation-insulin-sulphonylureas.
• 5. Rafiq, M, Flanagan, SE, Patch, AM, Shields, BM, Ellard, S, Hattersley, AT, Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31: 204-9.

Terms in the title (7)： アデノシン三リン酸 ,  メンバー ,  遺伝子変異 ,  新生児糖尿病 ,  幼児 ,  スルホニルウレア ,  治療